Evidence Hub

Acquired trichorrhexis nodosa in association with hyperthyroidism

M. Mathur, N. Thakur, Sunil Jaiswal, Srijana Maharjan

International Journal of Dermatology, 2023

5 citations

Abstract

s40257-018-0356-7 3 Syed K, Chaudhary H, Balu B. Pyoderma gangrenosum following COVID-19 infection. J Community Hosp Intern Med Perspect. 2021;11:601–3. https://doi.org/10.1080/20009666. 2021.1958492 4 Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021;46:1082–5. https://doi. org/10.1111/ced.14683 5 Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol. 2018;179(2):504–5. https://doi.org/10.1111/bjd. 16468 6 Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023:S0365-0596(23)00114-9. https://doi.org/10. 1016/j.abd.2023.03.001. 7 Maronese CA, Pimentel MA, Li MM, Genovese G, OrtegaLoayza AG, Marzan AV. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615–34. https://doi. org/10.1007/s40257-022-00699-8 8 Kozono K, Nakahara T, Kikuchi S, Itoh E, Kido-Nakahara M, Furue M. Pyoderma gangrenosum with increased levels of serum cytokines. J Dermatol. 2015;42(12):1186–8. https://doi.org/10. 1111/1346-8138.12970 9 Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31(2):e75–7. https://doi.org/10.1111/jdv. 13736

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free